{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T07:21:30Z","timestamp":1793172090760,"version":"4.5.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,13]],"date-time":"2025-07-13T00:00:00Z","timestamp":1752364800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014943","name":"Sarepta Therapeutics Inc","doi-asserted-by":"publisher","award":["SRP-LUMC-001"],"award-info":[{"award-number":["SRP-LUMC-001"]}],"id":[{"id":"10.13039\/100014943","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Nucleic Acids"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.omtn.2025.102625","type":"journal-article","created":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T16:07:55Z","timestamp":1752768475000},"page":"102625","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Using muscle homing peptide CyPep10 to deliver phosphorodiamidate morpholino oligomers in the mdx mouse"],"prefix":"10.1016","volume":"36","author":[{"given":"Anne-Fleur E.","family":"Schneider","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christa L.","family":"Tanganyika-de Winter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvana M.G.","family":"Jirka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuyu","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily G.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen","family":"Ha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anindita","family":"Mitra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marleen","family":"Luimes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan A.","family":"Oliver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Guerlavais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemieke","family":"Aartsma-Rus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtn.2025.102625_bib1","series-title":"StatPearls [Internet]. Treasure Island (FL)","article-title":"Duchenne Muscular Dystrophy","author":"Venugopal","year":"2023"},{"key":"10.1016\/j.omtn.2025.102625_bib2","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1056\/NEJM198805263182104","article-title":"Characterization of Dystrophin in Muscle-Biopsy Specimens from Patients with Duchenne\u2019s or Becker\u2019s Muscular Dystrophy","volume":"318","author":"Hoffman","year":"1988","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omtn.2025.102625_bib3","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41572-021-00248-3","article-title":"Duchenne muscular dystrophy","volume":"7","author":"Duan","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.omtn.2025.102625_bib4","first-page":"184","article-title":"The role of fibrosis in Duchenne muscular dystrophy","volume":"31","author":"Klingler","year":"2012","journal-title":"Acta Myol."},{"key":"10.1016\/j.omtn.2025.102625_bib5","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1016\/S0140-6736(19)32910-1","article-title":"Muscular dystrophies","volume":"394","author":"Mercuri","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.omtn.2025.102625_bib6","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1474-4422(09)70271-6","article-title":"DMD Care Considerations Working Group. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management","volume":"9","author":"Bushby","year":"2010","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.omtn.2025.102625_bib7","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1002\/mus.26490","article-title":"Intermittent glucocorticoid regimes for younger boys with Duchenne muscular dystrophy: Balancing efficacy with side effects","volume":"59","author":"McMillan","year":"2019","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.omtn.2025.102625_bib8","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1261\/rna.653607","article-title":"Antisense-mediated exon skipping: a versatile tool with therapeutic and research applications","volume":"13","author":"Aartsma-Rus","year":"2007","journal-title":"RNA"},{"key":"10.1016\/j.omtn.2025.102625_bib26","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/0888-7543(88)90113-9","article-title":"An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus","volume":"2","author":"Monaco","year":"1988","journal-title":"Genomics"},{"key":"10.1016\/j.omtn.2025.102625_bib9","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/humu.20918","article-title":"Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations","volume":"30","author":"Aartsma-Rus","year":"2009","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.omtn.2025.102625_bib10","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1093\/nar\/gkad067","article-title":"Critical Reviews and Perspectives Chemistry, structure and function of approved oligonucleotide therapeutics","volume":"51","author":"Egli","year":"2023","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2025.102625_bib11","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1001\/jama.2016.16437","article-title":"Approving a Problematic Muscular Dystrophy Drug: Implications for FDA Policy","volume":"316","author":"Kesselheim","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.omtn.2025.102625_bib12","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1002\/ana.25951","article-title":"Very Low Residual Dystrophin Quantity Is Associated with Milder Dystrophinopathy","volume":"89","author":"de Feraudy","year":"2021","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.omtn.2025.102625_bib13","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ymthe.2017.10.004","article-title":"Cyclic Peptides to Improve Delivery and Exon Skipping of Antisense Oligonucleotides in a Mouse Model for Duchenne Muscular Dystrophy","volume":"26","author":"Jirka","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2025.102625_bib14","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1073\/pnas.81.4.1189","article-title":"X chromosome-linked muscular dystrophy (mdx) in the mouse","volume":"81","author":"Bulfield","year":"1984","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2025.102625_bib15","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/jmr.630","article-title":"A brief introduction to cell-penetrating peptides","volume":"16","author":"Lundberg","year":"2003","journal-title":"J. Mol. Recognit."},{"key":"10.1016\/j.omtn.2025.102625_bib16","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.omtn.2022.08.019","article-title":"A cell-penetrating peptide enhances delivery and efficacy of phosphorodiamidate morpholino oligomers in mdx mice","volume":"30","author":"Gan","year":"2022","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2025.102625_bib17","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1016\/j.bbamem.2010.02.012","article-title":"Morpholinos and their peptide conjugates: therapeutic promise and challenge for Duchenne muscular dystrophy","volume":"1798","author":"Moulton","year":"2010","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.omtn.2025.102625_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00204-021-03184-z","article-title":"Pharmacology and toxicology of eteplirsen and SRP-5051 for DMD exon 51 skipping: an update","volume":"96","author":"Sheikh","year":"2022","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.omtn.2025.102625_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.crtox.2024.100182","article-title":"Comprehensive review of adverse reactions and toxicology in ASO-based therapies for Duchenne Muscular Dystrophy: From FDA-approved drugs to peptide-conjugated ASO","volume":"7","author":"Sabrina Haque","year":"2024","journal-title":"Curr. Res. Toxicol."},{"key":"10.1016\/j.omtn.2025.102625_bib20","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/543282","article-title":"Serum Enzyme Profiles Differentiate Five Types of Muscular Dystrophy","volume":"2015","author":"Zhu","year":"2015","journal-title":"Dis. Markers"},{"key":"10.1016\/j.omtn.2025.102625_bib21","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1080\/17425255.2021.1992382","article-title":"Antisense oligonucleotides: absorption, distribution, metabolism, and excretion","volume":"17","author":"Shadid","year":"2021","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.omtn.2025.102625_bib22","doi-asserted-by":"crossref","first-page":"5235","DOI":"10.1093\/nar\/gkaa299","article-title":"Phosphorothioate modified oligonucleotide-protein interactions","volume":"48","author":"Crooke","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2025.102625_bib23","doi-asserted-by":"crossref","first-page":"4405","DOI":"10.1093\/hmg\/ddp395","article-title":"A fusion peptide directs enhanced systemic dystrophin exon skipping and functional restoration in dystrophin-deficient mdx mice","volume":"18","author":"Yin","year":"2009","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtn.2025.102625_bib24","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1038\/mt.2010.151","article-title":"Functional rescue of dystrophin-deficient mdx mice by a chimeric peptide-PMO","volume":"18","author":"Yin","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2025.102625_bib25","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1038\/nbt759","article-title":"Systemically delivered antisense oligomers upregulate gene expression in mouse tissues","volume":"20","author":"Sazani","year":"2002","journal-title":"Nat. Biotechnol."}],"container-title":["Molecular Therapy Nucleic Acids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253125001799?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253125001799?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T20:34:39Z","timestamp":1777322079000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2162253125001799"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S2162253125001799"],"URL":"https:\/\/doi.org\/10.1016\/j.omtn.2025.102625","relation":{},"ISSN":["2162-2531"],"issn-type":[{"value":"2162-2531","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Using muscle homing peptide CyPep10 to deliver phosphorodiamidate morpholino oligomers in the mdx mouse","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Nucleic Acids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtn.2025.102625","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"102625"}}